Prolonged absorption of antimony(V) by the oral route from non-inclusion meglumine antimoniate-β-cyclodextrin conjugates

Biopharmaceutics and Drug Disposition

Volumn 31, Issue 2-3, 2010, Pages 109-119

  Ribeiro, Raul R ^a,b   Ferreira, Weverson A ^a   Martins, Patricia S ^a   Neto, Rubens L M ^a   Rocha, Olguita G F ^c   Le Moyec, Laurence ^d   Demicheli, Cynthia ^a   Frézard, Frédéric ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSIDADE FEDERAL DO RECÔNCAVO DA BAHIA   (Brazil)

^c Centro Tecnológico de Minas Gerais Belo Horizonte   (Brazil)

^d UNIVERSITÉ PARIS 13   (France)

Author keywords

Cyclodextrin; Dogs; Meglumine antimoniate; Oral route; Pharmacokinetics

Indexed keywords

ANTIMONY; BETA CYCLODEXTRIN; MEGLUMINE ANTIMONATE;

ANIMAL EXPERIMENT; ARTICLE; CIRCULAR DICHROISM; COMPLEX FORMATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG SOLUBILITY; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; GASTROINTESTINAL ABSORPTION; MOUSE; NONHUMAN; PHOTON CORRELATION SPECTROSCOPY; PHYSICAL CHEMISTRY; PROTON NUCLEAR MAGNETIC RESONANCE; SINGLE DRUG DOSE; SUSTAINED DRUG RELEASE;

ABSORPTION; ADMINISTRATION, ORAL; ANIMALS; ANTIMONY; BETA-CYCLODEXTRINS; CIRCULAR DICHROISM; DELAYED-ACTION PREPARATIONS; DOGS; FEMALE; MALE; MEGLUMINE; MICE; ORGANOMETALLIC COMPOUNDS;

EID: 77951062455     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.695     Document Type: Article

References (20)

1. Szejtli J. Introduction and general overview of cyclodextrin chemistry. Chem Rev 1998; 98: 1743-1754. (Pubitemid 128633435)
2. Hirayama F, Uekama K. Cyclodextrin-based controlled drug release system. Adv Drug Deliv Rev 1999; 36: 125-141. (Pubitemid 29074480)
3. Uekama K, Hirayama F, Irie T. Cyclodextrin drug carrier systems. Chem Rev 1998; 98: 2045-2076.
4. Frezard F, Demicheli C, Ribeiro RR. Pentavalent antimonials: new perspectives for old drugs. Molecules 2009; 14: 2317-2336.
5. Demicheli C, Ochoa R, da Silva JBB, et al. Oral delivery of meglumine antimoniate-beta-cyclodextrin complex for treatment of leishmaniasis. Antimicrob Agents Chemother 2004; 48: 100-103. (Pubitemid 38040183)
6. Martins PS, Ochoa R, Pimenta AMC, et al. Mode of action of β-cyclodextrin as an absorption enhancer of the water-soluble drug meglumine antimoniate. Int J Pharm 2006; 325: 39-47. (Pubitemid 44608216)
7. Frézard F, Martins PS, Bahia APCO, et al. Enhanced oral delivery of antimony from meglumine antimoniate/β-cyclodextrin nanoassemblies. Int J Pharm 2008; 347: 102-108. (Pubitemid 350186086)
8. Demicheli C, Frézard F, Lecouvey M, Garnier-Suillerot A. Antimony(V) complex formation with adenine nucleosides in aqueous solution. Biochim Biophys Acta 2002; 1570: 192-198.
9. Ferreira CS, Pimenta AMC, Demicheli C, Frézard C. Characterization of reactions of antimoniate and meglumine antimoniate with a guanine ribonucleoside at different pH. Biometals 2006; 19: 573-581. (Pubitemid 44291051)
10. Frézard F, Martins PS, Barbosa MCM, et al. New insights into the chemical structure and composition of the pentavalent antimonial drugs, meglumine antimonate and sodium stibogluconate. J Inorg Biochem 2008; 102: 656-665. (Pubitemid 351384687)
11. Demicheli C, Figueiredo TL, Carvalho S, Sinisterra RD, Lopes JC, Frézard F. Physico-chemical characterization of meglumine antimoniate. Biometals 1999; 12: 63-66.
12. Demicheli C, Ochoa R, Lula IS, Gozzo FC, Eberlin M, Frézard F. Pentavalent organoantimonial derivatives: two simple and efficient synthetic methods for meglumine antimonite. Appl Organomet Chem 2003; 17: 226-231.
13. Costantini S, Giordano R, Rizzica M, Benedetti F. Applicability of anodic-stripping voltammetry and graphite furnace atomic-absorption spectrometry to the determination of antimony in biological matrices: a comparative study. Analyst 1985; 110: 1355-1359.
14. Yamaoka K, Nakagawa T, Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978; 6: 165-175. (Pubitemid 8384279)
15. Valladares JE, Alberola J, Esteban M, Arboix M. Disposition of antimony after administration of N-methylglucamine antimoniate to dogs. Vet Rec 1996; 138: 181-183. (Pubitemid 26063058)
16. Poon R, Chu I. Effects of potassium antimony tartrate on rat erythrocytes phosphofructokinase activity. J Biochem Mol Toxicol 1998; 12: 227-233. (Pubitemid 128501681)
17. Sun H, Yan SC, Cheng WS. Interaction of antimony tartrate with the tripeptide glutathione. Eur J Biochem 2000; 267: 5450-5457.
18. Ferreira CS, Martins PS, Demicheli C, Brochu C, Ouellette M, Frezard F. Thiol-induced reduction of antimony(V) into antimony(III): a comparative study with trypanothione, cysteinyl-glycine, cysteine and glutathione. Biometals 2003; 16: 441-446.
19. Burguera JL, Burguera M, Petit de Pena Y, Lugo A, Anez N. Selective determination of antimony(III) and antimony(V) in serum and urine and of total antimony in skin biopsies of patients with cutaneous leishmaniasis treated with meglumine antimoniate. Trace Elem Med 1993; 10: 66-70.
20. Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 1997; 24: 684-703.